Replimune Group (NASDAQ:REPL) Stock: Insider Joseph Slattery Sells 5,200 Shares

Replimune Group, Inc. (NASDAQ:REPL) Director Joseph Slattery sold 5,200 shares of the stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $21.80, for a total value of $113,360.00. Following the transaction, the director owned 1,467 shares in the company, valued at $31,980.60. This trade represents a 78.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Replimune Group Stock Down 6.4%

Shares of NASDAQ:REPL opened at $21.78 on Thursday. The stock’s 50-day moving average price is $14.51 and its two-hundred day moving average price is $9.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 6.90. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $23.54.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. As a group, equities analysts expect that Replimune Group, Inc. will post -2.40 EPS for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

Large investors have recently modified their holdings of the company. AXQ Capital LP lifted its stake in shares of Replimune Group by 4.1% in the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock valued at $300,000 after purchasing an additional 1,056 shares in the last quarter. Walleye Capital LLC grew its holdings in shares of Replimune Group by 3.2% during the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after purchasing an additional 2,192 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Replimune Group by 30.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company’s stock worth $223,000 after purchasing an additional 4,050 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Replimune Group during the 3rd quarter worth approximately $64,000. Finally, Allworth Financial LP acquired a new stake in Replimune Group during the 2nd quarter worth approximately $62,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on REPL. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Leerink Partners lifted their price target on shares of Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Replimune Group in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.33.

About Replimune Group

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.